Form 4 for VCYT VERACYTE, INC.
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-02 · accession 0001649245-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | S - Sale | $36.16 | -13.4K | 117.3K | -10% | -$485.4K | |
| 2026-03-04 | 2026-03-02 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | F - Tax | $36.01 | -6,035 | 130.8K | -4% | -$217.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | S | D | 13,425 | $36.16 | 117,346 | D | — | — | (F3) Represents weighted average sales price. Sale prices for the transactions range from $35.78 to $36.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
| 2 | Common | Common Stock | 2026-03-02 | F | D | 6,035 | $36.01 | 130,771 | D | — | — |